when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

185 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT805 Endpoints604 BioPharma Dive231 onclive165 Fierce Biotech74 BioSpace71 raps32 fda press20 globenewswire health

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology6 Hematology

REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer
Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.
onclive · 2mo ago↗ source
Clinical Implementation and Surveillance Strategies
onclive · 2mo ago↗ source
Case Introduction and ctDNA as Emerging Risk Factor
onclive · 2mo ago↗ source

page 3 of 8

20

6

Infectious Disease4

ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies

Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.

onclive · 2mo ago↗ source

MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies

Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.

onclive · 2mo ago↗ source

Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question

New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.

onclive · 2mo ago↗ source

HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Response

HORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.

onclive · 2mo ago↗ source

Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)

Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.

onclive · 2mo ago↗ source

Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss

How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.

onclive · 2mo ago↗ source

Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer

Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.

onclive · 2mo ago↗ source

Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies

Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.

onclive · 2mo ago↗ source

Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice

Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.

onclive · 2mo ago↗ source

FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML

The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.

onclive · 2mo ago↗ source

FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma

The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.

onclive · 2mo ago↗ source

Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.

onclive · 2mo ago↗ source

Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSL

Ashley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.

onclive · 2mo ago↗ source

Future Directions in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono conclude the discussion by reflecting on the evolving future of radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC) and…

onclive · 2mo ago↗ source

Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer

Dr. Johann De Bono and Dr. Pedro Barata discuss the increasing complexity of personalized treatment decision-making in metastatic castration-resistant prostate cancer (mCRPC) as radiopharmaceutical…

onclive · 2mo ago↗ source

Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss the future direction of radiopharmaceutical therapies and emerging treatment strategies in metastatic castration-resistant prostate cancer (mCRPC).

onclive · 2mo ago↗ source

Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer

Dr. Johann De Bono and Dr. Pedro Barata discuss practical approaches to monitoring and managing toxicities associated with radiopharmaceutical therapies in metastatic castration-resistant prostate…

onclive · 2mo ago↗ source

Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castration-res…

onclive · 2mo ago↗ source

Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer

Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of treatment sequencing and patient selection for radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).

onclive · 2mo ago↗ source

Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics influence the use of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).

onclive · 2mo ago↗ source

Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer

Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus on radium…

onclive · 2mo ago↗ source

Consensus Recommendations Address Key Controversies in Lymphoma Management

Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.

onclive · 2mo ago↗ source